Cargando…

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Gallwitz, Baptist
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2016
Materias:	Diabetes Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813455/ https://www.ncbi.nlm.nih.gov/pubmed/29632584 http://dx.doi.org/10.17925/EE.2016.12.01.31

Ejemplares similares

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice
por: Fitchett, David H
Publicado: (2018)

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
por: Gallwitz, Baptist, et al.
Publicado: (2013)

The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2007)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
por: Gallwitz, Baptist
Publicado: (2015)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients
por: Mehta, Sanjana, et al.
Publicado: (2021)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
por: Mubashir, Muaz, et al.
Publicado: (2022)

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial
por: Larsen, Emil List, et al.
Publicado: (2017)

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
por: Pokharel, Arbinda, et al.
Publicado: (2021)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation
por: Ahmed, Mazhar, et al.
Publicado: (2023)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis
por: Fernandez Felix, Daniel A, et al.
Publicado: (2022)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019)

Post-surgical Euglycemic Diabetic Ketoacidosis in a Patient on Empagliflozin in the Intensive Care Unit
por: Bteich, Fernand, et al.
Publicado: (2019)

PSUN250 Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes
por: Alzenaidi, Ahlam, et al.
Publicado: (2022)

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
por: Liao, Hung-Wei, et al.
Publicado: (2017)

Early Recognition of Overweight Hyperglycaemia May Improve Clinical Outcomes in Type 2 Diabetes
por: Chockalingam, Anand, et al.
Publicado: (2023)

SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
por: MS, ANEESH
Publicado: (2019)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Initial Combination Empagliflozin and Linagliptin Improves Kidney Fibrotic Marker in Patients With Type 2 Diabetes: A Randomized Controlled Trial
por: Sathavarodom, Nattapol, et al.
Publicado: (2021)

Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes
por: Naegeli, A N, et al.
Publicado: (2010)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Detection of Euglycemic Diabetic Ketoacidosis During Thoracic Surgery 75 Hours After Empagliflozin Discontinuation
por: Nishida, Ai, et al.
Publicado: (2022)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Developments in the Management of Type 1 and Type 2 Diabetes
por: Mathieu, Chantal
Publicado: (2018)

Treatment of Type 2 Diabetes in Youth
por: Flint, Amanda, et al.
Publicado: (2011)

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
por: Stinkens, Kirsten, et al.
Publicado: (2016)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6vu432kpf15licfgn6ci4ksle